Phosphoglycerate mutase deficiency (PGMD) is a rare inherited metabolic disorder. This condition is caused by a deficiency of the enzyme phosphoglycerate mutase, which plays a key role in glycolysis and the Krebs cycle. Phosphoglycerate mutase is required to convert 3-phosphoglycerate to 2-phosphoglycerate, which leads to the formation of ATP, which is necessary for normal cellular function. Deficiency of this enzyme leads to the accumulation of intermediate metabolites and decreased ATP levels, which in turn affects the functioning of various organs and systems, especially the muscular and nervous systems. Clinical manifestations can range from mild to severe and include muscle weakness, spastic paralysis, and other neurological impairment.
History of the disease and interesting historical facts
Phosphoglycerate mutase deficiency was first described in the scientific literature in the mid-20th century. In 1969, researchers Cottingham and Rangaisli studied cases of patients with muscle weakness syndrome, which subsequently led to the isolation of the enzyme and its role in glycolysis. The advent of molecular biology in the 1980s opened up new horizons for understanding the mechanisms of the disease, which made it possible to identify the genetic nature of the deficiency of this enzyme. Researchers subsequently determined that mutations in the PGAM2 gene, responsible for the synthesis of phosphoglycerate mutase, lead to insufficient function of the enzyme. This discovery was an important step in the development of genetics and medical genetic counseling.
Epidemiology
Phosphoglycerate mutase deficiency is a rare disorder with limited knowledge compared to other metabolic disorders. The incidence of PGDM is reported to be 1 in 1 million live births. However, this may vary by ethnicity and geographic region. For example, some populations may have higher rates of mutations in the PGAM2 gene due to genetic drift or consanguineous marriages. In addition, the incidence may be underestimated due to the large number of asymptomatic cases, making it difficult to accurately determine the true incidence of the disease.
Genetic predisposition to this disease
The genetic basis of phosphoglycerate mutase deficiency is associated with the inheritance of mutations in the PGAM2 gene, which is located on chromosome 7. This gene is responsible for the synthesis of an isoenzyme involved in carbohydrate metabolism. Several mutations in the PGAM2 gene have been identified to date, leading to functional impairment of the enzyme. For example, some mutations can lead to a complete loss of enzyme activity, while others can lead to a partial loss, which determines the severity of clinical manifestations. Inheritance mechanisms are most often recessive, which means that two defective alleles are required for the disease to manifest - from each parent.
Because the disease is genetic, family history can provide important information about the risk of developing the disease in other generations.
Risk factors for the development of this disease
Risk factors for phosphoglycerate mutase deficiency are primarily related to genetic predisposition, but may also include:
- Heredity: the presence of cases of the disease in the family increases the likelihood of its manifestation in future generations.
- Cross-genetic factors: mutations in associated genes affecting carbohydrate metabolism.
- Inbreeding rates: the more closely related marriages in a population, the higher the probability of passing on genetic mutations.
- Physical activity: In some cases, intense physical activity may worsen the symptoms of the disease in susceptible individuals.
- Environmental factors: Exposure to adverse environmental conditions (eg, toxic substances) may contribute to the development of specific forms of metabolic diseases, although a direct link to DFGM requires further research.
Diagnosis of this disease
Diagnosis of phosphoglycerate mutase deficiency includes a set of measures aimed at identifying clinical manifestations and confirming genetic predisposition:
- Main symptoms: manifestations may include muscle weakness, fatigue, spastic paralysis, as well as psychoneurological symptoms.
- Laboratory tests: the key method is the determination of phosphoglycerate mutase activity in cells, as well as the analysis of biochemical markers in the blood and urine.
- Radiological examinations: MRI and CT can help visualize changes in muscle and nerve structures, especially in cases of severe clinical symptoms.
- Other diagnostic tests: Molecular genetic testing can identify specific mutations in the PGAM2 gene, which can confirm the diagnosis.
- Differential diagnosis: It is important to exclude other metabolic disorders and neuromuscular diseases such as muscular dystrophy and myasthenia gravis, syndromes associated with metabolic disorders.
Treatment
Treatment of phosphoglycerate mutase deficiency can be complex and depends on the clinical picture:
- General treatment: involves physical rehabilitation and lifestyle modifications with an emphasis on balanced nutrition and adequate physical activity.
- Pharmacological treatment: currently there are no specific drugs, but metabolic agents to support energy metabolism, such as creatine and coenzyme Q10, are used.
- Surgical treatment: In cases where there is severe muscle weakness and contractures, surgical intervention may be considered to correct the impairment.
- Other treatments: Physical therapy and the use of assistive devices (orthotics) can improve the quality of life of patients.
List of medications used to treat this disease
Although there is no specific treatment for the disease, some medications may be used to improve symptoms:
- Creatine
- Coenzyme Q10
- Prednisolone (for inflammatory processes)
- Amino acid complexes
- Vitamin and mineral preparations
Disease monitoring
Monitoring of patients with phosphoglycerate mutase deficiency requires regular observation:
- Control stages: regular physical examinations, assessment of muscle strength and tone.
- Prognosis: Disease manifestations can vary, but most patients with early diagnosis can have a satisfactory quality of life.
- Complications: muscular dystrophy and other secondary diseases associated with lack of energy may develop.
Age-related features of the disease
Phosphoglycerate mutase deficiency can manifest itself at any age, but the manifestations of the disease have their own characteristics depending on age:
- Childhood: Symptoms may be severe and include hypotension, "falling" syndrome, and difficulty with physical activity.
- Adolescence: Patients may experience worsening of the condition due to hormonal changes and increased physical activity.
- Adulthood: Many patients adapt or experience mild symptoms that may include increased fatigue.
- Elderly: manifestations of the disease may be aggravated, requiring more careful monitoring and therapy.
Questions and Answers
- What are the main symptoms of phosphoglycerate mutase deficiency? The main symptoms include muscle weakness, fatigue, spastic paralysis, and potentially neuropsychiatric disorders.
- How is the disease diagnosed? Diagnosis includes laboratory tests for enzyme activity, molecular genetic testing, and imaging studies.
- What treatment is used for this pathology? Treatment includes physical rehabilitation, drug therapy to support metabolism, and, in some cases, surgery.
- What is the prognosis for patients with phosphoglycerate mutase deficiency? The prognosis can be positive with early diagnosis and adherence to treatment recommendations, but complications associated with lack of energy are possible.
- Is it possible to prevent the disease? Prevention is only possible at the level of genetic counseling for families with a high risk of inheriting this disease.
